Group 1 - The stock price of Aier Eye Hospital (300015) closed at 10.59 yuan on February 26, 2026, down by 1.03%, with a turnover rate of 0.56%, a trading volume of 443,300 shares, and a transaction amount of 470 million yuan [1] - The company aims to enhance its core competitiveness by focusing on patient-centered care, improving medical technology, and innovating service models to meet diverse patient needs, thereby increasing brand influence and achieving sustainable growth [2] - The company is not required to issue performance forecasts according to the Shenzhen Stock Exchange's rules, and it plans to disclose its annual report on April 24, 2026, indicating that operations for the fiscal year 2025 are normal [3] Group 2 - On February 26, 2026, the net outflow of funds from major investors was 25.70 million yuan, while retail investors saw a net inflow of 19.64 million yuan [4] - The trading information indicates that speculative funds had a net inflow of 6.05 million yuan on the same day [5]

Group 1 - The Hunan Province held a conference to promote the development of the private economy, awarding 100 outstanding private entrepreneurs for their contributions to regional economic growth and the construction of a modern industrial system [1][2] - Notable recipients include leaders from over 20 listed companies, showcasing the vitality and potential of the private economy in Hunan [1] - Key figures from companies such as SANY Heavy Industry, Lens Technology, Aier Eye Hospital, and others were recognized, representing various advantageous industrial sectors including engineering machinery, consumer manufacturing, biomedicine, and new energy technology [1][2] Group 2 - Executives from several listed companies' subsidiaries also received awards, highlighting the collaborative development within Hunan's industrial chain [2] - Entrepreneurs at critical stages of the IPO process were also honored, indicating the effective cultivation of Hunan's private economic tier [2] - The awarded entrepreneurs span key industries such as engineering machinery, green agricultural products, biomedicine, and advanced materials, playing a crucial role in transforming traditional industries and fostering new emerging sectors [2]

Core Viewpoint - The company focuses on patient-centered care, continuously enhancing medical technology and innovative service models to meet diverse patient needs, thereby increasing brand influence and achieving sustainable growth [1] Group 1 - The company aims to satisfy patients, reassure families, and earn societal respect [1] - The strategy is designed to improve brand influence over time [1] - The emphasis is on high-quality and sustainable growth [1]

爱尔眼科（300015.SZ）2月26日在投资者互动平台表示，根据《深圳证券交易所创业板股票上市规则 （2024 年修订）》6.2.2款规定，公司无需发布业绩预告。2025年度经营正常，将于2026年4月24日按时 披露年度报告。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问近期会发布业绩快报吗？ ...

Core Viewpoint - The collaboration between Jinan Aier Eye Hospital and Meimu Medical aims to enhance the quality of customized prosthetic eye services, addressing the needs of patients with eye defects and improving their confidence and quality of life [1][3][5]. Group 1: Collaboration Significance - The partnership is a crucial step in expanding the service boundaries of Jinan Aier Eye Hospital, aligning with the "whole lifecycle eye health" concept [3][5]. - The introduction of customized prosthetic eye services will fill the gap in high-quality services in the region, allowing patients to access professional care without traveling to major cities [3][11]. Group 2: Clinical Value - The collaboration will leverage the hospital's clinical strengths to provide precise pre-operative assessments, intra-operative adaptations, and post-operative follow-up support for prosthetic eye customization [5][9]. - A customized prosthetic eye is essential for patients to regain social confidence and return to normal life, addressing both aesthetic and psychological needs [5][7]. Group 3: Patient-Centric Approach - The partnership emphasizes a patient-centered service philosophy, optimizing service processes and providing personalized care, including green channels for appointments and post-operative guidance [7][11]. - The initiative aims to enhance patient dignity and confidence through high-quality prosthetic eye services, incorporating psychological support and educational outreach [7][11]. Group 4: Technological Advancements - Meimu Medical has developed advanced polymer prosthetic eye technology, achieving realistic effects that set industry standards [9][11]. - The collaboration will focus on continuously upgrading the customization technology to meet patient needs more effectively [9][11]. Group 5: Future Outlook - The partnership is expected to promote the standardization and personalization of prosthetic eye services in Jinan and surrounding areas, contributing to the "Healthy China 2030" strategy in the field of ophthalmology [11].

Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

Summary of Conference Call on Healthcare Services and Pharmacy Sector Industry Overview - The focus is on the healthcare services and pharmacy sectors within the pharmaceutical industry, particularly consumer-oriented segments, which are currently viewed positively due to historical low valuations after a prolonged adjustment period [1][2]. Key Points and Arguments Healthcare Services - The healthcare services sector has experienced significant declines, with current valuations at historical lows, indicating a potential for recovery by 2026 [1]. - Specific companies highlighted for their optimistic 2026 guidance include Tongce Medical, Gushengtang, and Aier Eye Hospital, all expected to show double-digit growth [1][2]. - The recovery in the sector is anticipated to be driven by improvements in supply structure and consumer environment, leading to a business rebound [2]. - Aier Eye Hospital is introducing new consumer-oriented surgical procedures, which may increase average transaction values despite stable surgical volumes [2]. Market Trends - Data from October 2025 shows positive growth in outpatient services in cities like Chongqing and Tianjin, with increases of 5-6% and 13-14% respectively [3]. - The overall trend indicates a recovery in both service volume and pricing, particularly in consumer-oriented medical fields like ophthalmology [3][4]. AI Integration - AI is expected to empower healthcare service companies, with applications like Ant Group's AI health app showing significant user growth, indicating a new growth driver for leading healthcare service firms [4][5]. Pharmacy Sector - The pharmacy sector is experiencing notable improvements in performance since Q3 2025, with leading companies showing consistent same-store sales growth [6]. - The sector is supported by government policies aimed at increasing industry concentration and chain store rates, which are expected to drive medium-term performance [6][7]. - Companies like Yifeng Pharmacy and Dazhong Pharmacy are highlighted for their strong cash flow and dividend yields, with Dazhong reporting a 60% dividend payout ratio [6][7]. Online vs. Offline Dynamics - The online pharmacy market is growing rapidly, but it serves a different demographic compared to traditional pharmacies, which cater more to older consumers [7][8]. - The online pharmacy market is projected to grow significantly, driven by products like GLP-1, but the overall growth rate may stabilize as both online and offline markets adjust [9][10]. Regulatory Environment - Recent government policies emphasize enhancing pharmacy service capabilities and supporting prescription outsourcing, which could lead to increased revenue opportunities for pharmacies [13][14]. - The focus on compliance and competition is expected to benefit larger pharmacy chains with established networks and resources for mergers and acquisitions [17]. Home Medical Devices - The home medical device sector is poised for growth due to an aging population and increasing health awareness, with significant potential in health monitoring devices like blood pressure monitors and glucose meters [18][19]. - Companies such as Yuyue Medical and Sanofi are recommended for their strong growth prospects in this segment [21]. Conclusion - The healthcare services, pharmacy, and home medical device sectors are expected to experience a bottom reversal, driven by improving fundamentals and supportive government policies. Key players in these sectors are well-positioned to capitalize on these trends, making them attractive investment opportunities moving forward [1][21].

Investment Rating - The industry investment rating is "Positive" (maintained) [5][41]. Core Insights - The medical services and pharmacy sectors have undergone significant adjustments since 2021, with valuations and performance returning to historically low levels. For instance, leading companies like Aier Eye Hospital, Tongce Medical, and Yifeng Pharmacy have seen their total market values decline by 73.5%, 81.9%, and 45.9% respectively since the Spring Festival of 2021 [1][16]. - The consumer medical industry is experiencing an improvement in competition and safety margins, aided by the implementation of relevant policies and a potential recovery in consumer willingness to spend [2]. - The offline pharmacy sector is benefiting from policy incentives and an improved competitive landscape, with significant support for prescription outflow and industry restructuring [3][32]. Summary by Sections 1. Valuation Bottoming and Low Holdings - The medical services and pharmacy sectors have faced prolonged adjustments, leading to valuations at historically low levels. The public fund holdings in these sectors have also decreased [10][11]. - The leading companies in the industry have seen substantial market value adjustments, indicating a low public fund holding ratio [16]. 2. Accumulating Reversal Momentum - The medical services and pharmacy sectors are expected to experience a dual recovery in performance and valuation, driven by improved competition and policy clarity [21]. - The medical services sector is witnessing a gradual recovery in income growth, particularly in the ophthalmology sector, which has seen a slowdown in revenue growth after a rapid recovery period [22]. - The pharmacy sector is experiencing a shift towards health service platforms, supported by policy changes that encourage pharmacies to expand their service offerings [33]. 3. Investment Views - Focus on leading companies in the medical services sector that have strong chain expansion capabilities and supply chain advantages, such as Aier Eye Hospital and Tongce Medical, which are expected to benefit from consumer upgrades and market demand [4][37]. - In the pharmacy sector, attention should be given to leading chains with strong supply chain advantages and management capabilities, such as Yifeng Pharmacy and Dazhenglin, which are well-positioned to capture market share and benefit from policy changes [4][37].

Core Viewpoint - The exposure of Xiangyang Hengtai Kang Hospital and other mental health institutions for allegedly fabricating treatment projects and misappropriating medical insurance funds has raised concerns about governance risks associated with Aier Eye Hospital, despite the company's claim that the involved hospital is not part of its listed company system [1] Stock Performance - Following the incident, Aier Eye Hospital's stock price dropped by 3.82% on February 6, closing at 11.07 yuan, and further declined to 10.33 yuan by February 13, marking a cumulative decrease of approximately 10.3% from the pre-incident closing price of 11.51 yuan on February 5 [2] - On February 13, there was a net outflow of 363 million yuan in main capital, with a significant increase in cumulative net outflow over the past five days, indicating a cautious market sentiment [2] Company Status - Although the involved hospital is not included in the listed company's financial statements, it shares a common actual controller (Chen Bang) with Aier Eye Hospital, and the chairman of the involved hospital, Zhang Yuwen, also serves as the party secretary of Aier Eye Hospital and president of Aier Medical Investment Group, highlighting governance connections [3] - Historical violations include at least 10 companies associated with Aier Eye Hospital that have faced penalties for medical insurance violations such as itemized billing and duplicate charges, indicating that compliance issues with related parties are not isolated incidents [3] Company Fundamentals - The company's net profit attributable to shareholders decreased by 9.76% year-on-year in the first three quarters of 2025, with the gross profit margin falling to 49.27%, partly due to increased depreciation and amortization from new hospital openings [4] - Aier Eye Hospital continues to advance its "1+8+N" graded chain network strategy, but the complexity of management has increased due to rapid expansion, and this incident may intensify market skepticism regarding its cross-system management capabilities [4] Event Impact - The incident has created short-term pressure on Aier Eye Hospital's stock price and capital flow, primarily reflecting market concerns about the risk transmission from non-listed company systems to the listed platform [5] - In the medium to long term, attention should be paid to improvements in corporate governance transparency and the progress of compliance rectification for related businesses [5]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in treating primary progressive multiple sclerosis (PPMS), marking a significant advancement in the treatment landscape [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with unmet needs in PPMS due to limited treatment options [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial for PPMS included 985 patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11][24]. - The safety profile of Fenebrutinib was comparable to Ocrelizumab, with a similar incidence of adverse events [22][24]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x [35][36]. - Specific segments like chemical pharmaceuticals and biological products have higher valuations, indicating investor confidence in these areas [35][36].